Impact of Fenofibrate on Type 2 Diabetes Patients with Features of the Metabolic Syndrome: Subgroup Analysis From FIELD.

Curr Cardiol Rev · 2010 · PMC2892076 · PMID 21532777

Europe PMC DOI

hedged sentence

0.0520

closest p · 1.0× alpha

0.0520

boldest claim

The sentences

failed to reach statistical significanceP=0.052so close (0.05 < p ≤ 0.1)

placebo in patients with the metabolic syndrome was similar in magnitude to the effect of fenofibrate in the overall population, but marginally failed to reach statistical significance (P=0.052).

also in 6,035 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.